-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1367 Mouse Model of Splenic Marginal Zone Lymphoma to Decipher the Pathogenetic Implications of NOTCH2 and KLF2 Mutations

Program: Oral and Poster Abstracts
Session: 603. Lymphoid Oncogenesis: Basic: Poster I
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Lymphomas, B Cell lymphoma, Genomics, Diseases, Lymphoid Malignancies, Biological Processes, Molecular biology, Pathogenesis
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Deborah Piffaretti, PhD1*, Martin Richard Faderl, PhD1*, Federico Jauk, MD1*, Adalgisa Condoluci, MD1,2, Lodovico Terzi Di Bergamo1*, Gabriela Forestieri1*, Ricardo Koch, PhD1*, Katia Pini1*, Joyce Marques de Almeida, MD1*, Ilaria Romano, MD1,2, Matin Salehi1*, Alessio Bruscaggin, PhD1*, Simone Bocchetta, PhD1*, Georgia Alice Galimberti1*, Maria Cristina Pirosa, MD1,2, Alexandar Tzankov, MD, PhD3*, Emanuele Zucca, MD4,5 and Davide Rossi, MD, PhD1,2,4

1Institute of Oncology Research, Laboratory of Experimental Hematology, Bellinzona, Switzerland
2Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
3Medical Genetics and Pathology, University of Basel, Basel, Switzerland
4Università della Svizzera italiana, Faculty of Biomedical Science, Lugano, Switzerland
5Division of Medical Oncology, Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale, Bellinzona, Switzerland

Background. Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous disease with a variable clinical course and genetic profile. Our group identified a high-risk subset of patients, termed NNK-SMZLs (58% of cases), associated with poorer survival. This genetic cluster is characterized by the co-occurrence of heterozygous mutations that activate NOTCH2 and heterozygous or homozygous genetic lesions that disrupt KLF2. To investigate the role of NOTCH2 and KLF2 genetic alterations in the development of SMZL, we created genetically engineered mouse models (GEMMs) with conditional alleles that either activated Notch2, inactivated Klf2, or combined both alterations specifically in B cells. Short-term (ST) experiments focused on monitoring changes in the B-cell compartment and understanding how Notch2 and Klf2 mutations cooperate in affecting quantity and quality of splenic B-cell subsets. Long-term (LT) experiments aimed to assess lymphoma type and penetrance.

Methods. We generated a new GEMM by crossbreeding wherein concomitant Klf2 and Notch2 mutations are under the control of Cd19Cre [Klf2fl/+/Notch2ICfl/+/Cd19Cre+/- (Klf2het/Notch2IChet) or Klf2fl/fl/Notch2ICfl/+/Cd19Cre+/- (Klf2hom/Notch2IChet) in the C57BL/6background]. Genotypes expressing single Notch2ICfl/+/Cd19Cre+/- (Notch2IChet), Klf2fl/+/Cd19Cre+/- (Klf2het), Klf2fl/fl/Cd19Cre+/- (Klf2hom) or Cd19Cre+/- (control) were also tested. In ST experiments, 3 age/sex-matched 8–12-week-old mice were immunized with NP-KLH or vehicle and sacrificed for analysis after 28 days. Spleen was analyzed for histopathologic features. Splenocytes were analyzed by high dimensional flow cytometry using the BD FACSymphony, exploiting 41 B, T and myeloid markers. Additionally, Chromium Next GEM-X Single Cell Gene Expression (scRNA-seq) on splenocyte, Visium CytAssist for FFPE Spatial Gene Expression profile across spleen compartments and Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) on sorted marginal zone (MZ) B cells, follicular (FO) B cells, transitional 1 B-cells and transitional 2 B-cells were performed in ST experiments, and results will be presented. In LT experiment 25 age/sex-matched 8–12-week-old mice/genotype underwent chronic immunization with sheep red blood cells and were monitored over 20 months. Spleen, liver, bone marrow and lymph node were extracted for FFPE block/single cell suspension preparation and assessed by two independent pathologists in blind. Lymphoma development was diagnosed based on morphology and phenotype following the classification of mouse lymphomas.

Results. In ST experiment Klf2hom mice exhibited enlarged FO and MZ areas, while Notch2IChet mice revealed reduced FO and expanded MZ with blurred marginal sinus (interphase). In turn, Klf2hom/Notch2IChet mice displayed features of Klf2hom mice but also a blurred marginal sinus (interphase). FACSymphony analysis depicted increased proportion of MZ B cells at the expenses of FO B and myeloid cells in Notch2IChet and Klf2hom/Notch2IChet compared to Klf2hom and control. LT mice with either Klf2hom/Notch2IChet or Klf2het/Notch2IChet showed higher incidences of SMZL (36%, p=0.002 and 54%, p<0.0001, respectively) and DLBCL (20% and 12%, respectively) compared to single mutants (Notch2IChet: SMZL 19%, DLBCL 14%; Klf2hom: SMZL 10%, DLBCL 0%; Klf2het: SMZL 13%, DLBCL 0%) or controls (SMZL: 5%; DLBCL: 3%).

Conclusions. Our data support the oncogenic roles of NOTCH2 and KLF2 in SMZL development, indicating that their co-occurrence increases lymphoma penetrance. The lymphoproliferative phenotype in double mutant mice closely models human SMZL, including aggressive progression to DLBCL.

Disclosures: Condoluci: AbbVie, BeiGene, Janssen Cilag AG, BMS: Honoraria; Gilead: Research Funding. Romano: Bei Gene: Consultancy, Other: Travel grant. Pirosa: BeiGene: Honoraria, Other: travel grant; Janssen: Other: travel grant. Zucca: AbbVie, AstraZeneca, BeiGene, and Gilead: Other: Travel grants; AbbVie, BeiGene, BMS, Curis, Eli/Lilly, Incyte, Ipsen, Merck, and Roche: Consultancy; Abbvie: Honoraria; AstraZeneca, Beigene, Celgene/BMS, Incyte, Janssen, Roche: Research Funding. Rossi: AbbVie, Adaptive, AstraZeneca, BeiGene, Janssen: Research Funding; AbbVie, AstraZeneca, BeiGene, BMS, Janssen, Lilly: Consultancy, Honoraria.

*signifies non-member of ASH